Future Considerations for the Treatment of R/M HPV-Positive HNSCC

Panelists discuss how emerging areas in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) research include novel immunotherapy combinations, biomarker development for treatment selection, targeted therapies against new molecular pathways, and strategies to overcome resistance to existing treatments.

EP: 1.Introduction and Incidence of HPV-Positive Head and Neck Cancer

EP: 2.Understanding HPV-Positive HNSCC: Disease Presentation and Risk Factors

EP: 3.Navigating Treatment for HPV-Positive HNSCC Patients

EP: 4.Academic Perspectives for the Management of HPV-Positive HNSCC

EP: 5.Updates From VERSATILE-002: Pembrolizumab Plus PDS0101 (HPV-16–Targeted Cancer Vaccine) in HPV-Positive HNSCC

EP: 6.Emerging Phase 3 Trial: Pembrolizumab Plus PDS0101 (HPV-16 Targeted Cancer Vaccine) in HPV-Positive HNSCC (VERSATILE-003)

EP: 7.Treatment Insights for R/M HPV-Positive HNSCC

Now Viewing

EP: 8.Future Considerations for the Treatment of R/M HPV-Positive HNSCC

Video content above is prompted by the following:

• What areas for future research in the treatment of R/M HNSCC should clinicians keep an eye on?

Related Videos